ORXE News Alert Ore Pharmaceuticals (ORXE) 0.2100 10/01/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ore Pharmaceuticals (ORXE) 0.2100 $ORXE

Novavax Announces Management Promotions
Thomson Reuters ONE - Thu Jun 19, 3:26PM CDT
GAITHERSBURG, Md., June 19, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants, announced today a number of promotions within its management team.

NYSE Questions Houston American Energy Corp.'s Unusual Market Activity
ACCESSWIRE - Wed Mar 12, 8:25AM CDT
Houston American Energy Corp. (NYSE: HUSA) stock volume soared Mar. 11, with 2,384,313 shares changing hands, nearly five times its three-month average volume of 502,308 shares.

Canfor Corporation and Canfor Pulp Products Inc. Announce Fourth Quarter Results Conference Call
Marketwire - Wed Jan 15, 5:19PM CST
Canfor Corporation (TSX: CFP) and Canfor Pulp Products Inc. (TSX: CFX) will hold a joint conference call on Thursday, February 6, 2014 at 8:00 AM PST to discuss their respective fourth quarter 2013 financial and operating results. To participate in the call, please dial one of the following numbers:

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Functional Dyspepsia
M2 - Mon Sep 02, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lbqxmb/functional_non) has announced the addition of the "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia. Functional (Non Ulcer) Dyspepsia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Functional (Non Ulcer) Dyspepsia. - A review of the Functional (Non Ulcer) Dyspepsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Functional (Non Ulcer) Dyspepsia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Eisai Co., Ltd. - Zeria Pharmaceutical Co Ltd - Ore Pharmaceuticals Inc - AGI Therapeutics plc - Ironwood Pharmaceuticals, Inc. - RaQualia Pharma Inc. For more information visit http://www.researchandmarkets.com/research/lb...tional_non About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Gastric Ulcers - Pipeline Review, H1 2013
M2 - Thu Jul 18, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t63njg/gastric_ulcers) has announced the addition of the "Gastric Ulcers - Pipeline Review, H1 2013" report to their offering. 'Gastric Ulcers - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastric Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastric Ulcers. Scope - A snapshot of the global therapeutic scenario for Gastric Ulcers. - A review of the Gastric Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Gastric Ulcers pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Gastric Ulcers Therapeutics Development - Takeda Pharmaceutical Company Limited - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ore Pharmaceuticals Inc - Sihuan Pharmaceutical Holdings Group Ltd. - HeliCure AB Drug Profiles - vonoprazan - DWJ-206 - Helicobacter Pylori Vaccine - ebselen - PMKS-005 - Acid Pump Antagonists - Anaprazole For more information visit http://www.researchandmarkets.com/research/t6...ric_ulcers

Ulcers - Pipeline Review, H1 2013
M2 - Fri Jul 12, 8:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4fgbql/ulcers_pipeline) has announced the addition of the "Ulcers - Pipeline Review, H1 2013" report to their offering. The research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcers. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by a team of experts. Scope - A snapshot of the global therapeutic scenario for Ulcers. - A review of the Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-spec

Ore Pharmaceuticals Inc - Product Pipeline Review - 2012
M2 - Mon Feb 18, 4:08AM CST
Summary

Inflammatory Bowel Disease - Pipeline Review, H2 2012 Out Now
M2 - Fri Jan 04, 10:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/pf73r6/inflammatory) has announced the addition of Global Markets Direct's new report "Inflammatory Bowel Disease - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Inflammatory Bowel Disease - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ActivTrak's Fast 500 Rank Needs Investor Perspective

Updated Category News Views 60

Rank 488 is the sort of trophy that deserves a raised eyebrow, not confetti. ActivTrak made Deloitte's 2026 Technology Fast 500 after posting 101.1% revenue growth from 2022 through 2025, its sixth appearance on the list since 2020. That is real progress, and repeat recognition says this was not a one-quarter sugar high. Still, a Fast 500 ranking is a growth screen, not a...

Continue Reading
Ridgeline’s Dome Roof Award Signals Durable Craft Demand

Updated Category News Views 69

A faceted dome in the Alabama woods is about as far from a cookie-cutter reroof as it gets. Ridgeline Roofing & Restoration’s 2026 Excellence Award from Brava Roof Tile matters because the job in Pell City demanded the sort of painstaking field execution that separates a capable contractor from a crew merely moving shingles fast. Geometry Is Where Easy Claims Go to Die...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 85

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Valley Family Health Breach Notice Raises Hard Questions

Updated Category News Views 53

Seven months is a long time for sensitive patient data to sit inside an unresolved security story. Valley Family Health Care, Inc. says it suffered a network disruption on or about March 13, 2026, investigated with outside cybersecurity specialists, and ultimately determined that an unauthorized actor accessed and acquired certain files. The formal notification process...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 120

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 92

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 106

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 94

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
DocLinq Takes Aim at Care Gaps Between Office Visits

Updated Category News Views 182

Healthcare's most expensive loose ends often pile up after the appointment ends. DocLinq, launched from Columbia, Maryland, is taking a run at that awkward stretch between office visits, where records sit in separate systems, chronic-care follow-up gets uneven, and patients are expected to remember far more than any human reasonably can. This is not a story about AI...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

MINISH Technology's Milestone: First U.S. Veneers Certification Success

Updated Category News Views 201

MINISH Technology Concludes First U.S. Veneers Course Health-tech company MINISH Technology Inc. has recently achieved a remarkable milestone by successfully completing its first MINISH Veneers course in the United States, certifying 22 dedicated dentists. This event highlights a significant step forward in the company’s commitment to advancing dental education and...

Continue Reading
Exciting Developments for Stellar V Capital Corp.'s Trading Options

Updated Category News Views 130

Stellar V Capital Corp. Announces Upcoming Trading Changes NEW YORK — Stellar V Capital Corp., a rising star in the acquisition space, has exciting news for its investors. Beginning March 24, 2025, holders of the units sold during the Company’s initial public offering will have the option to trade the Class A ordinary shares separately from the associated warrants....

Continue Reading
DelNorte’s Groundbreaking Data Tokenization Initiative Unveiled

Updated Category News Views 1405

Revolutionizing Public Data Management with DelNorte In an exciting move aimed at improving how public data is handled, DelNorte has partnered with a significant government body to initiate a cutting-edge data tokenization project. This initiative is centered around the introduction of the DTV Token, a vital component of DelNorte's innovative Terra Vision ecosystem,...

Continue Reading
Celebrating Success at the AMPLIFY A|E|C Conference

Updated Category News Views 67

WB Engineers+Consultants at the AMPLIFY A|E|C Conference Recently, WB Engineers+Consultants was proud to represent its ethos of innovation and excellence at the AMPLIFY A|E|C 2024 conference, a key event dedicated to the architecture, engineering, and construction (A/E/C) sectors. This distinguished conference was organized by the Society for Marketing Professional...

Continue Reading
Calix Faces Legal Fire Over Alleged Securities Missteps

Updated Category News Views 51

Calix Hits a Legal Snag: What's at Stake? In the gritty world of stock trading, nothing gets folks more riled up than talk of lawsuits—and here comes Calix, Inc. (NYSE: CALX) caught in a thorny one. Straight out of Los Angeles, the DJS Law Group beams a flare into the sky, reminding investors of a class action lawsuit tagged to violations of the Securities Exchange Act...

Continue Reading